Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06371482 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

Name: Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01) — clinical trial record (NCT06371482)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorHebei Medical University Fourth Hospital

Started2023-06-01

View on ClinicalTrials.gov ↗

Record status

This record was last updated June 17, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Amendment history

2024-06-13

Study Status v1

Re-verified, no change to tracked fields

2024-04-14

Original filing

Hebei Medical University Fourth Hospital

53 trials monitored

See 1 trial at risk

Small Cell Lung Cancer

539 trials monitored

See 30 trials at risk

This trial aims to assess efficacy and safety of durvalumab combined with chemoradiotherapy for limited stage small cell lung cancer.

Trial Details

NCT Number	NCT06371482
Lead Sponsor	Hebei Medical University Fourth Hospital
Conditions	SCLC, Limited Stage
Enrollment	58 participants
Start Date	2023-06-01
Primary Completion	2024-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-06-17